Drug interactions and pharmacokinetics

Drug interactions and pharmacokinetics features

• Geriatric HIV: living with multiple medical conditions will become the norm as population ages

  In fifteen years' time, the clinical needs of Dutch people living with HIV will have changed substantially due to three quarters of them being over the...

  From:  News

• 

  One in five Kenyan patients suffers major interactions between HIV drugs and other medicines

  Nearly 20% of patients in an HV treatment programme in Kenya have suffered major interactions between their HIV drugs and other prescribed medicines, a study...

  From:  HIV & AIDS treatment in practice

Drug interactions and pharmacokinetics news from aidsmap

• Frequent drug-drug interactions in older people with HIV in France

  Drug-drug interactions are common in people over the age of 65 living with HIV and this substantially increases healthcare costs in France. Published in Open Forum Infectious Diseases, a new study has revealed that as many as 17% of ...

  19 June 2019 | Alain Volny-Anne

• Co-administration of dolutegravir-based treatment and short course of rifapentine/isoniazid (3HP) well tolerated in people living with HIV

  Co-administration of dolutegravir-based antiretroviral therapy and short course (12 weeks) of rifapentine/isoniazid (3HP) for people living with HIV needing preventative treatment for latent tuberculosis (TB) infection was well tolerated with no adverse reactions, the Conference on Retroviruses and Opportunistic Infections ...

  12 March 2019 | Carole Leach-Lemens

• Potential drug interactions among people with HIV taking statins

  Drug interactions remain a potential problem for HIV-positive people who are treated with statins, according to research published in the December issue of the Journal of the American Heart Association. Potential interactions were detected between statins and modern antiretroviral drugs – ...

  09 January 2019 | Michael Carter

• Italian study shows growth in heart and kidney problems in people living with HIV

  Reduced kidney function, high blood pressure and cardiovascular disease have each become more common in a large cohort of Italians living with HIV followed since 2004, with a majority of people now having high cholesterol and high blood pressure, ...

  28 December 2018 | Keith Alcorn

• Transgender women taking PrEP have lower levels of PrEP drugs, especially in rectal tissues, than cisgender men

  A study presented at last month’s HIV Research for Prevention conference (HIVR4P) in Madrid shows that transgender women who are taking feminising hormones and also taking pre-exposure prophylaxis (PrEP) have levels of the PrEP drugs tenofovir and emtricitabine in ...

  09 November 2018 | Gus Cairns

• The long tail of injectable PrEP is especially long for women

  Around four in ten women and one in ten men taking injectable cabotegravir as pre-exposure prophylaxis (PrEP) still have evidence of the drug in their body around 18 months after their last injection, Raphael Landovitz of the University of ...

  25 October 2018 | Roger Pebody

• PrEP does not lower feminising hormone level in transgender women

  Using Truvada (tenofovir DF/emtricitabine) for HIV prevention does not lower levels of feminising hormones, offering reassurance for transgender women who are concerned about drug interactions, according to a presentation at the 22nd International AIDS Conference (AIDS 2018) in Amsterdam.  Tenofovir levels in ...

  25 July 2018 | Liz Highleyman

• Potential interactions between ART and other medications present in over half of older HIV-positive people

  Over half of older HIV-positive people are at risk of experiencing an interaction between their anti-HIV drugs and medications taken for the treatment of non-HIV-related conditions, Italian investigators report in the online edition of the Journal ...

  31 May 2018 | Michael Carter

• TAF only superior to TDF when used with a boosting agent

  The benefits of tenofovir alafenamide (TAF) over tenofovir disoproxil fumarate (TDF) may have been overstated, according to the results of a meta-analysis published in the Journal of Virus Eradication. It was only when used in an ...

  10 April 2018 | Michael Carter

• Twice-daily dolutegravir is safe and effective when used alongside TB treatment

  Twice-daily dosing of dolutegravir when combined with the tuberculosis (TB) drug rifampicin is safe and effective and will allow dolutegravir to be used alongside TB treatment as part of first-line antiretroviral therapy (ART), according to results of the INSPIRING ...

  07 March 2018 | Keith Alcorn

More news

Drug interactions and pharmacokinetics news selected from other sources

• Aging HIV population face complicated rheumatologic care

  As the national population of patients who are HIV-positive continues to age, rheumatologists will be increasingly called on to manage routine care for crystal disease, osteoarthritis, soft tissue rheumatism and other conditions, according to Leonard Calabrese, DO, of the Cleveland Clinic.

  22 May 2019 | Healio

• One third of French HIV group uses illicit drugs, often risking antiretroviral interactions

  One in 3 people in a 286-person French HIV group took illicit drugs that sometimes posed a risk of severe interactions with antiretrovirals. Many potential interactions involved the boosting agents ritonavir or cobicistat.

  17 May 2019 | NATAP

• Some people may have genes that hamper a drug's HIV protection

  Some people’s genes may stop an antiretroviral drug from protecting them against HIV, a genetics study suggests.

  13 May 2019 | Science News

• Do Feminizing Hormones Impact Efficacy of PrEP Drugs?

  A team of investigators is examining why some transgender women taking hormones may need higher levels of PrEP medication.

  29 April 2019 | Contagion Live

• The largest study involving transgender people is providing long-sought insights about their health

  The research examines once taboo questions about the impacts of gender transition. The European Network for the Investigation of Gender Incongruence (ENIGI) is the largest scientific study of transgender people in the world, now with 2600 participants, and is unique because it is prospective, studying the impact of hormone and other therapies on their health over the long term.

  25 April 2019 | Nature

• Elvitegravir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1

  Pharmacokinetic data indicate exposure of elvitegravir boosted with cobicistat (Genvoya, Stribild) is lower during the second and third trimesters of pregnancy than postpartum. Low elvitegravir exposure may be associated with an increased risk of treatment failure and an increased risk of HIV-1 transmission to the unborn child, and therefore elvitegravir/cobicistat should not be used during pregnancy.

  17 April 2019 | Medicines and Healthcare products Regulatory Agency

• Efavirenz and rifampicin together reduce levels of injectable contraception

  Women with HIV receiving depot medroxyprogesterone acetate (DMPA), with efavirenz (EFV)-based ART and rifampicin (RIF)-based TB treatment, had lower MPA plasma levels compared with women not receiving the two drugs.

  29 March 2019 | HIV i-Base

• Double-dose levonorgestrel implant does not overcome interaction with efavirenz

  Using two levonorgestrel (LNG) implants does not fully overcome the drug-drug interaction with efavirenz (EFV) – according to findings from a pharmacokinetic (PK) evaluation of double-dose LNG in Ugandan women receiving EFV-based ART.

  29 March 2019 | HIV i-Base

• TB CAB statement on safety of using bedaquiline and delamanid together

  he Global TB Community Advisory Board (TB CAB) welcomes the important finding from the AIDS Clinical Trials Group Deliberate Trial that newer drugs bedaquiline and delamanid are safe to use together. These findings should erase any remaining reluctance to use these two important drugs together, as the benefits of these safer drugs outweigh the risks--especially for patients with drug-resistant TB who have few other treatment options.

  14 March 2019 | TB Online

• Double doses of darunavir given with rifampicin lead to high rates of hepatoxicity

  Adjusted doses of darunavir/ritonavir (DRV/r) with rifampicin (RIF) were associated with unacceptable risk of hepatotoxicity and a reduction in DRV trough concentrations in a pharmacokinetic (PK) study, conducted in South Africa, presented at CROI 2019.


  12 March 2019 | HIV i-Base

More news